N | n | Univariate analysis | Adjusted analysis | |||||
---|---|---|---|---|---|---|---|---|
IRR | (95 % IC) | p-value | aIRR | (95 % CI) | p-value | |||
Antiretroviral therapy (ART) and cotrimoxazole exposure | <0.01 | <0.01 | ||||||
On ART - On cotrimoxazole | 667 | 4 | 0.06 | (0.01-0.28) | <0.01 | 0.05 | (0.01-0.24) | <0.01 |
Off ART - On cotrimoxazole | 83 | 1 | 0.13 | (0.01-1.25) | 0.08 | 0.11 | (0.01-1.08) | 0.06 |
On ART - Off cotrimoxazole | 332 | 17 | 0.58 | (0.17-1.99) | 0.38 | 0.58 | (0.17-1.99) | 0.39 |
Off ART - Off cotrimoxazole | 35 | 3 | 1 | - | - | 1 | - | - |
Immunodeficiency for Age a | 0.48 | 0.09 | ||||||
Severe | 69 | 3 | 2.19 | (0.65-7.39) | 0.21 | 4.59 | (1.32-15.98) | 0.02 |
Moderate | 106 | 3 | 1.40 | (0.41-4.73) | 0.59 | 2.09 | (0.61-7.19) | 0.24 |
No/Missing | 942 | 19 | 1 | - | - | 1 | - | - |
Age | 0.17 | |||||||
<5 years | 144 | 6 | 2.82 | (0.98-8.13) | 0.05 | Not included | ||
[5-10[years | 443 | 11 | 1.64 | (0.66-4.09) | 0.28 | |||
≥10 years | 530 | 8 | 1 | - | - | |||
Centres | <0.01 | |||||||
CHU de Cocody | 182 | 1 | 1 | - | - | |||
CHU de Yopougon | 344 | 4 | 2.13 | (0.24-19.08) | 0.50 | Not included | ||
CePReF | 322 | 8 | 4.66 | (0.58-37.30) | 0.15 | |||
CIRBA | 212 | 2 | 1.74 | (1.56-19.25) | 0.65 | |||
MTCT-Plus | 57 | 10 | 35.20 | (4.51-275.03) | <0.01 |